Cefpodoxime

C difficile risk
Medium
Oral Bioavailability
Moderate

Dosing

200mg PO Q12H

CrCl<30 mL/minute

  • Administer Q24H

General Information

  • Chronic bronchitis (acute exacerbation)

  • Otitis media (acute)

  • Pharyngitis/tonsillitis

  • Pneumonia (community-acquired)

  • Sinusitis (acute maxillary)

  • Skin and skin structure infections (uncomplicated)

  • Urinary tract infections (uncomplicated)

Laboratory

  • Renal function

Clinical

  • Hypersensitivity

  • Diarrhea

  • Other GI effects

  • GI effects - diarrhea, nausea, abdominal pain

  • Hypersensitivity reactions

  • C. difficile

Antimicrobial class: Third generation cephalosporin - Oral

Pregnancy category: B

Average serum half life: 2-3 hours

CSF penetration: Poor

Lung penetration: Moderate

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.